Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Substudy of A5257

NCT00851799 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT00851799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00851799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Substudy of A5257
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Observational
Overall status
Completed
Start date
June 30, 2009
Completion date
June 30, 2013
Enrollment
334 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection